Agenus Inc. (AGEN) rose 8.67% to $4.3250, up $0.3450, after reporting third-quarter 2025 results and announcing key clinical and regulatory advances.
The company disclosed that France has granted reimbursed access for its BOT/BAL therapy in MSS mCRC, and a global Phase 3 trial (BATTMAN) is set to launch in Q4 2025 across 100+ sites.
On the day of the announcement, AGEN experienced unusually heavy trading volume as investors reacted to the news. The stock's 52-week range is $1.14 - $4.50.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.